1,244,533LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable, accrued liabilities and other current liabilities$
92,097Deferred revenue86—Total current liabilities78,15492,097Convertible debt497,083497,083Other long-term liabilities19,74169,689Total liabilities594,978658,869Stockholders' equity:Common stock, $0.001 par value: 250,000,000 shares authorized at December 31, 2009 and September 30, 2010; 100,961,922 and 102,464,509 shares issued and outstanding at December 31, 2009 and September 30, 2010, respectively101103Additional paid-in capital899,950948,394Company common stock held by Nonqualified Deferred Compensation Plan(1,715)(2,176)Accumulated other comprehensive income (loss)933(1,581)Accumulated deficit(577,084)(359,076)Total stockholders' equity322,185585,664Total liabilities and stockholders' equity$
1,244,533(1) December 31, 2009 balances were derived from the audited consolidated financial statements. BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONSFor the Three and Nine Months Ended September 30, 2009 and 2010(In thousands, except for per share data, unaudited)Three Months Ended September 30,Nine Months Ended September 30,2009201020092010Revenues:Net product revenues$
271,224Collaborative agreement revenues6481302,025507Royalty and license revenues1,7761,0613,7802,922Total revenues80,80797,750237,574274,653Operating expenses:Cost of sales (excludes amortization of developed product technology)14,97018,00349,18049,816Research and development26,99139,36687,673105,112Selling, general and administrative28,66738,34887,762109,625Intangible asset amortization and contingent consideration463,9722,9146,206Total operating expenses70,67499,689227,529270,759Income (loss) from operations10,133(1,939)10,0453,894Equity in the loss
|SOURCE BioMarin Pharmaceutical Inc.|
Copyright©2010 PR Newswire.
All rights reserved